// App-Quantinova.ai

POS1067 (2022) : DOMAINS CONTRIBUTING TO MINIMAL DISEASE ACTIVITY ACHIEVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB

Researchers

Presenter

  • L. Coates

Principal Investigators

  • P. Rahman

  • P. J. Mease

  • M. Shawi

  • E. Rampakakis

  • A. Kollmeier

  • X. L. Xu

  • S. D. Chakravarty

  • I. Mcinnes

  • L. S. Tam

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Memorial University of Newfoundland, Craig L Dobbin Genetics Research Centre, St John’s, Canada

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America

  • McGill University, Department of Psychiatry, Montreal, Canada

  • JSS Medical Research, Inc, Scientific Affairs, Montreal, Canada

  • Janssen Research & Development, LLC, Immunology, San Diego, CA, United States of America

  • Janssen Scientific Affairs, LLC, Immunology, Horsham, United States of America

  • Drexel University College of Medicine, Rheumatology, Philadelphia, United States of America

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

  • The Chinese University of Hong Kong, Medicine & Therapeutics, Hong Kong, China

Locations

  • United Kingdom

  • Canada

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Fibromyalgia

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Malondialdehyde

  • Janus kinase

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved